Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Pharmaceuticals, Inc.”

376 pharma patents match "Alnylam Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 376
Index total 30,257
Page 15 / 16

Quick answer

This filtered view shows 376 pharmaceutical patents matching "Alnylam Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

376 results for “Alnylam Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 7902168

    Compositions and methods for inhibiting expression of Nav1.8 gene

    Alnylam Pharmaceuticals, Inc. · Granted Mar 8, 2011 · Expires Mar 3, 2031

    granted

  2. US 7893224

    Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase

    Alnylam Pharmaceuticals, Inc. · Granted Feb 22, 2011 · Expires Feb 17, 2031

    granted

  3. US 7888498

    Compositions and methods for inhibiting expression of IKK-B gene

    Alnylam Pharmaceuticals, Inc. · Granted Feb 15, 2011 · Expires Feb 10, 2031

    granted

  4. US 7875711

    Compositions and methods for inhibiting expression of XBP-1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Jan 25, 2011 · Expires Jan 20, 2031

    granted

  5. US 7871985

    Compositions and methods for inhibiting expression of factor VII gene

    Alnylam Pharmaceuticals, Inc. · Granted Jan 18, 2011 · Expires Jan 13, 2031

    granted

  6. US 7868160

    Compositions and methods for inhibiting expression of anti-apoptotic genes

    Alnylam Pharmaceuticals, Inc. · Granted Jan 11, 2011 · Expires Jan 6, 2031

    granted

  7. US 7846908

    RNAi modulation of TGF-beta and therapeutic uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Dec 7, 2010 · Expires Dec 2, 2030

    granted

  8. US 7846907

    Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene

    Alnylam Pharmaceuticals, Inc. · Granted Dec 7, 2010 · Expires Dec 2, 2030

    granted

  9. US 7829693

    Compositions and methods for inhibiting expression of a target gene

    Alnylam Pharmaceuticals, Inc. · Granted Nov 9, 2010 · Expires Nov 4, 2030

    granted

  10. US 7812150

    RNAi modulation of Aha and therapeutic uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Oct 12, 2010 · Expires Oct 7, 2030

    granted

  11. US 7790878

    RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Sep 7, 2010 · Expires Sep 2, 2030

    granted

  12. US 7786290

    Double-stranded ribonucleic acid with increased effectiveness in an organism

    Alnylam Pharmaceuticals, Inc. · Granted Aug 31, 2010 · Expires Aug 26, 2030

    granted

  13. US 7772387

    Oligonucleotides comprising a modified or non-natural nucleobase

    Alnylam Pharmaceuticals, Inc. · Granted Aug 10, 2010 · Expires Aug 5, 2030

    granted

  14. US 7772200

    iRNA agents targeted to the Rho-A gene

    Alnylam Pharmaceuticals, Inc. · Granted Aug 10, 2010 · Expires Aug 5, 2030

    granted

  15. US 7763590

    Compositions and methods for inhibiting expression of a mutant gene

    Alnylam Pharmaceuticals, Inc. · Granted Jul 27, 2010 · Expires Jul 22, 2030

    granted

  16. US 7759320

    Compositions and methods for inhibiting expression of a gene from the Ebola

    Alnylam Pharmaceuticals, Inc. · Granted Jul 20, 2010 · Expires Jul 15, 2030

    granted

  17. US 7749978

    Compositions and methods for inhibiting expression of Huntingtin gene

    Alnylam Pharmaceuticals, Inc. · Granted Jul 6, 2010 · Expires Jul 1, 2030

    granted

  18. US 7745418

    Compositions and methods for inhibiting viral replication

    Alnylam Pharmaceuticals, Inc. · Granted Jun 29, 2010 · Expires Jun 24, 2030

    granted

  19. US 7745608

    Modified iRNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Jun 29, 2010 · Expires Jun 24, 2030

    granted

  20. US 7737265

    RNAi modulation of HIF-1 and therapeutic uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jun 15, 2010 · Expires Jun 10, 2030

    granted

  21. US 7723512

    Oligonucleotides comprising a non-phosphate backbone linkage

    Alnylam Pharmaceuticals, Inc. · Granted May 25, 2010 · Expires May 20, 2030

    granted

  22. US 7723317

    RNAi modulation of ApoB and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted May 25, 2010 · Expires May 20, 2030

    granted

  23. US 7718629

    Compositions and methods for inhibiting expression of Eg5 gene

    Alnylam Pharmaceuticals, Inc. · Granted May 18, 2010 · Expires May 13, 2030

    granted

  24. US 7691824

    Compositions and methods for inhibiting expression of a gene from the JC virus

    Alnylam Pharmaceuticals, Inc. · Granted Apr 6, 2010 · Expires Apr 1, 2030

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.